Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CIBA-GEIGY's ESTRADERM (ESTRADIOL) TRANSDERMAL PATCH EFFECTIVENESS

Executive Summary

CIBA-GEIGY's ESTRADERM (ESTRADIOL) TRANSDERMAL PATCH EFFECTIVENESS in the treatment of post-menopausal symptoms has been "adequately demonstrated," FDA's Fertility and Maternal Health Drugs Advisory Cmte. unanimously agreed at its Dec. 19 meeting. Asked by FDA if "the efficacy of Estraderm ]has[ been adequately demonstrated despite its inability in one study not to decrease gonadotrophic secretion below 50 mIU," the cmte. voted yes. Cmte. consultant David Archer, MD, University of Pittsburgh School of Medicine, commented: "I think Estraderm is definitely efficacious" and the gonadotropic level obtained with the drug appears to be the same as that obtained with conjugated equine estrogen. Ciba-Geigy's largest study was a 10-week placebo controlled comparison of Estraderm .1 mg to Ayerst's Premarin conjugated equine estrogen .625 mg and 1.25 mg tabs in 112 postmenopausal women who had been stabilized on Premarin. The firm reported that Estraderm provided "essentially equivalent control" of postmenopausal symptoms such as hot flashes. FDA's questions to the cmte. centered on the efficacy of Estraderm. For example, FDA asked if the "presence of equilin due to an inadequate washout period ]in one particular study[ biased the evidence for the efficacy of Estraderm TTS?" Noting that the "issues of safety" had already been resolved, Ad Hoc Cmte. Chairman George Tagatz, MD, University of Minnesota, said that because subjects as they "came off Premarin went into the treated group ]while[ others went into the placebo group . . . the study would have biased the results toward no effect" instead of toward a positive effect. FDA also asked if "the proposed labeling ]should[ indicate potentially serious skin reactions." Based on Ciba-Geigy's studies, in which patients using Estraderm had skin reactions ranging from no reaction to transitory partial erethema at the site of occlusion, the cmte. agreed that a warning against "serious" skin reactions was unnecessary. Reflecting cmte. consensus, cmte. member Martin Pernoll, MD, Tulane University School of Medicine, said: "I think that the information we were provided about their potential labeling is quite clear; they indicate that only localized irritation has been observed at the site and I don't think that needs further clarification." Several cmte. members noted that patient compliance with the bi-weekly application of Ciba-Geigy's patch might be improve if the company used a calendar or colored patch wrappers in the packaging of the product so that patients would be reminded of when to put on a new patch and when to take progesterone. Tagatz commented, "I like the calendar; then they always know what day of the month they're always supposed to be on Provera ]upjohn's medroxyprogesterone[ and they know what day of the month they're supposed to take estrogen." Ciba-Geigy said it would consider the cmte.'s suggestions for packaging of the product. Estraderm, which utilizes Alza's transdermal patch delivery system, has been studied using the hip or abdomen as the area of application. National Institutes of Health cmte. consultant Florence Haseltine, MD, commented that the location of the patch might also cause compliance problems. She said: "There is a real question about location of the patch because of compliance. I think a woman's choice of where those things are placed makes a considerable amount of difference" in compliance. Ciba-Geigy noted that it would have to do additional studies in patch application on other parts of the body for the labeling to give patients a choice of application location.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

Latest Headlines
See All
UsernamePublicRestriction

Register

PS009440

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel